company background image
4111 logo

Chi Sheng Pharma & Biotech TPEX:4111 Stock Report

Last Price

NT$28.35

Market Cap

NT$1.7b

7D

-2.6%

1Y

-1.9%

Updated

12 Jun, 2024

Data

Company Financials

Chi Sheng Pharma & Biotech Co., Ltd

TPEX:4111 Stock Report

Market Cap: NT$1.7b

4111 Stock Overview

Engages in the manufacturing, processing, sale, and import and export trade of pharmaceuticals, medical products, cosmetics, health foods, and medical equipment in Taiwan and internationally.

4111 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance2/6
Financial Health5/6
Dividends3/6

Chi Sheng Pharma & Biotech Co., Ltd Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Chi Sheng Pharma & Biotech
Historical stock prices
Current Share PriceNT$28.35
52 Week HighNT$34.90
52 Week LowNT$24.35
Beta0.21
1 Month Change9.25%
3 Month Change9.04%
1 Year Change-1.90%
3 Year Change21.41%
5 Year Change17.88%
Change since IPO112.22%

Recent News & Updates

Recent updates

Read This Before Buying Chi Sheng Pharma & Biotech Co., Ltd (GTSM:4111) For Its Dividend

Apr 06
Read This Before Buying Chi Sheng Pharma & Biotech Co., Ltd (GTSM:4111) For Its Dividend

A Look At The Fair Value Of Chi Sheng Pharma & Biotech Co., Ltd (GTSM:4111)

Mar 10
A Look At The Fair Value Of Chi Sheng Pharma & Biotech Co., Ltd (GTSM:4111)

Should Weakness in Chi Sheng Pharma & Biotech Co., Ltd's (GTSM:4111) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?

Feb 01
Should Weakness in Chi Sheng Pharma & Biotech Co., Ltd's (GTSM:4111) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?

Here's What You Should Know About Chi Sheng Pharma & Biotech Co., Ltd's (GTSM:4111) 4.2% Dividend Yield

Jan 05
Here's What You Should Know About Chi Sheng Pharma & Biotech Co., Ltd's (GTSM:4111) 4.2% Dividend Yield

Estimating The Fair Value Of Chi Sheng Pharma & Biotech Co., Ltd (GTSM:4111)

Dec 10
Estimating The Fair Value Of Chi Sheng Pharma & Biotech Co., Ltd (GTSM:4111)

Shareholder Returns

4111TW PharmaceuticalsTW Market
7D-2.6%2.0%1.9%
1Y-1.9%5.8%25.3%

Return vs Industry: 4111 underperformed the TW Pharmaceuticals industry which returned 5.8% over the past year.

Return vs Market: 4111 underperformed the TW Market which returned 25.3% over the past year.

Price Volatility

Is 4111's price volatile compared to industry and market?
4111 volatility
4111 Average Weekly Movement5.1%
Pharmaceuticals Industry Average Movement4.2%
Market Average Movement4.7%
10% most volatile stocks in TW Market8.5%
10% least volatile stocks in TW Market2.2%

Stable Share Price: 4111 has not had significant price volatility in the past 3 months.

Volatility Over Time: 4111's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1962n/an/awww.cscp.com.tw

Chi Sheng Pharma & Biotech Co., Ltd engages in the manufacturing, processing, sale, and import and export trade of pharmaceuticals, medical products, cosmetics, health foods, and medical equipment in Taiwan and internationally. Its products portfolio includes antibiotics and chemotherapeutic agents; plasma substitutes and amino acid preparations; water nutrients and electrolyte preparations; vitamins; hepatotropic agents; hormones and adrenal cortical steroids; autonomic nerves agents; antihistamines and antipruritics; antipyretics and analgesics; antitussives and anti-asthmas; gastro-intestinal preparations; local anesthetic preparations; hemodialysis concentrate and external solutions; peritoneal dialysis solutions; and others. The company also offers medical devices, fat emulsion products, anesthetic products, hemostatics solutions, food products, functional drinks, skin care products, and veterinary medicinal products.

Chi Sheng Pharma & Biotech Co., Ltd Fundamentals Summary

How do Chi Sheng Pharma & Biotech's earnings and revenue compare to its market cap?
4111 fundamental statistics
Market capNT$1.65b
Earnings (TTM)NT$73.08m
Revenue (TTM)NT$1.06b

22.1x

P/E Ratio

1.5x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
4111 income statement (TTM)
RevenueNT$1.06b
Cost of RevenueNT$730.29m
Gross ProfitNT$334.60m
Other ExpensesNT$261.52m
EarningsNT$73.08m

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)1.28
Gross Margin31.42%
Net Profit Margin6.86%
Debt/Equity Ratio10.5%

How did 4111 perform over the long term?

See historical performance and comparison

Dividends

3.5%

Current Dividend Yield

78%

Payout Ratio
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.